POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Clinical trials for POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis study tests a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is either related to prior cancer treatment or developed from other blood disorders. The goal is to fin…
Matched conditions: POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
Experimental drug shows promise for rare bone marrow cancer
Disease control OngoingThis study tests a drug called elotuzumab in 15 adults with a type of bone marrow cancer called myelofibrosis that has a specific genetic mutation (JAK2). The goal is to see if the drug can shrink an enlarged spleen, improve anemia, and reduce symptoms. Participants receive the d…
Matched conditions: POLYCYTHEMIA VERA, POST-POLYCYTHEMIC MYELOFIBROSIS PHASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:59 UTC